Orchestra BioMed Holdings Inc.
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -174.3% | – | -284.0% | – | -53.7% | +190.0% | -5.2% | +5.5% | -21.4% | -54.2% | -37.5% | +136.6% | +25.5% | +26.9% | -74.4% | +243.1% | -3.7% | +3.0% | +3,490.8% | -99.6% | -20.0% | – | |
| – | – | – | – | +77.1% | -29.0% | +31.8% | -27.6% | +42.9% | -6.7% | -5.4% | -17.0% | +22.7% | -24.1% | +102.4% | +30.1% | -59.3% | +54.5% | -14.7% | -24.1% | +4.5% | +6.5% | +4.1% | +80.4% | -72.8% | – | |
| – | – | – | – | -181.2% | – | -294.8% | – | -58.6% | +224.6% | -5.1% | +6.7% | -23.1% | -56.1% | -52.6% | +186.0% | +43.4% | +25.2% | -78.8% | +322.6% | -4.1% | +2.8% | +3,701.2% | -99.9% | +250.0% | – | |
| – | – | – | – | -13.9% | +38.8% | -3.5% | -1.6% | +44.8% | +17.3% | +27.9% | +9.4% | +3.0% | +0.7% | -0.5% | +7.1% | +22.1% | +4.2% | -5.4% | +22.9% | +2.8% | +1.3% | +19.9% | -6.2% | +5.1% | – | |
| – | – | – | – | – | – | – | – | +18.9% | +79.1% | -36.8% | +32.3% | +20.6% | +19.3% | -34.0% | +40.9% | +9.7% | -12.4% | +4.1% | +6.1% | +0.0% | +13.3% | +2.7% | -12.6% | -8.5% | – | |
| – | +351.0% | +40.1% | +5,310.5% | -12.6% | +24.9% | -4.9% | +10.3% | +34.0% | +40.1% | -2.6% | +16.4% | +9.1% | +7.9% | -15.0% | +18.0% | +17.8% | -1.9% | -2.3% | +17.0% | +1.9% | +5.0% | +14.1% | -8.4% | +1.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -426.9% | – | – | |
| – | – | – | – | – | – | – | – | +4.2% | – | – | – | – | – | – | – | – | – | – | – | – | +1,330.6% | +48.2% | +7.6% | +115.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -431.3% | – | – | |
| – | – | – | – | – | – | – | – | -119.8% | – | – | – | – | – | – | -98.9% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -431.3% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -379.0% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.